Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers

被引：0
|
作者：
Henk van der Poel
Laurence Klotz
Gerald Andriole
Abdel-Rahmène Azzouzi
Anders Bjartell
Olivier Cussenot
Freddy Hamdy
Markus Graefen
Paolo Palma
Arturo Rodriguez Rivera
Christian G. Stief
机构：
[1] Netherlands Cancer Institute,Department of Urology
[2] University of Toronto,Division of Urology, Sunnybrook Health Science Centre
[3] Washington University St Louis,Division of Urology, Department of Surgery
[4] CHU d’Angers,Service d’Urologie
[5] Sahlgrenska Academy at the University of Gothenburg,Department of Urology, Institute of Clinical Sciences
[6] UPMC Univ Paris 06,Institute Universitaire de Cancerologie
[7] GRC-05,Nuffield Department of Surgical Sciences
[8] ONCOTYPE-Uro,Martini
[9] University of Oxford,Clinic Prostate Cancer Center
[10] University Medical Center Hamburg-Eppendorf,Department of Urology
[11] Universidade Estadual de Campinas,Department of Urology, Klinikum Großhadern, University Hospital Munich
[12] Hospital General Tlahuac,Großhadern
[13] Ludwig-Maximillians-University München,undefined
来源：
World Journal of Urology | 2015年 / 33卷
关键词：
Prostate cancer; Focal therapy; Active surveillance; Low risk; Intermediate risk; Consensus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：907 / 916
页数：9
相关论文
共 50 条
  • [21] Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
    Peter Albers
    Thomas Wiegel
    Heinz Schmidberger
    Roswitha Bussar-Maatz
    Martin Härter
    Glen Kristiansen
    Peter Martus
    Christoph Meisner
    Stefan Wellek
    Klaus Grozinger
    Peter Renner
    Martin Burmester
    Fried Schneider
    Michael Stöckle
    World Journal of Urology, 2021, 39 : 65 - 72
  • [22] Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
    Valentin H. Meissner
    Mira Woll
    Donna P. Ankerst
    Stefan Schiele
    Jürgen E. Gschwend
    Kathleen Herkommer
    World Journal of Urology, 2021, 39 : 3763 - 3770
  • [23] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
    Sherer, Michael, V
    Leonard, Austin J.
    Nelson, Tyler J.
    Guram, Kripa
    De Moraes, Gustavo Rodrigues
    Javier-Desloges, Juan
    Kane, Christopher
    McKay, Rana R.
    Rose, Brent S.
    Bagrodia, Aditya
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67
  • [24] Active Surveillance-Is It Feasible for Intermediate-risk Localised Prostate Cancer?
    Mukherjee, Subhabrata
    Promponas, Ioannis
    Petrides, Neophytos
    Hossain, Dafader
    Abbaraju, Jayasimha
    Madaan, Sanjeev
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 17 - 24
  • [25] Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model
    Benard, Antoine
    Duroux, Thomas
    Robert, Gregoire
    BJU INTERNATIONAL, 2019, 124 (06) : 962 - 971
  • [26] Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience
    Bandelier, Q.
    Bastide, C.
    Charvet, A. -L
    Leclercq, L.
    Gondran-Tellier, B.
    Campagna, J.
    Long-Depaquit, T.
    Daniel, L.
    Rossi, D.
    Lechevallier, E.
    Baboudjian, M.
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (01):
  • [27] Making a case “against” focal therapy for intermediate-risk prostate cancer
    Paolo Gontero
    Giancarlo Marra
    Dogu Teber
    Shahrokh Shariat
    Selami Albayrak
    Rafael Coelho
    Simon Tanguay
    Badrinath Konety
    World Journal of Urology, 2021, 39 : 719 - 728
  • [28] Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
    Masic, Selma
    Washington, Samuel L., III
    Carroll, Peter R.
    CURRENT OPINION IN UROLOGY, 2017, 27 (03) : 231 - 237
  • [29] Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes
    Enikeev, Dmitry
    Morozov, Andrey
    Taratkin, Mark
    Barret, Eric
    Kozlov, Vasiliy
    Singla, Nirmish
    Gomez Rivas, Juan
    Podoinitsin, Alexey
    Margulis, Vitaly
    Glybochko, Petr
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : E739 - E753
  • [30] Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach
    Baboudjian, Michael
    Breda, Alberto
    Roumeguere, Thierry
    Uleri, Alessandro
    Roche, Jean-Baptiste
    Touzani, Alae
    Lacetera, Vito
    Beauval, Jean-Baptiste
    Diamand, Romain
    Simone, Guiseppe
    Windisch, Olivier
    Benamran, Daniel
    Fourcade, Alexandre
    Fiard, Gaelle
    Durand-Labrunie, Camille
    Roumiguie, Mathieu
    Sanguedolce, Francesco
    Oderda, Marco
    Barret, Eric
    Fromont, Gaelle
    Dariane, Charles
    Charvet, Anne-Laure
    Gondran-Tellier, Bastien
    Bastide, Cyrille
    Lechevallier, Eric
    Palou, Joan
    Ruffion, Alain
    Van der Bergh, Roderick C. N.
    Peltier, Alexandre
    Ploussard, Guillaume
    WORLD JOURNAL OF UROLOGY, 2023, 41 (05) : 1301 - 1308
12345